ADOCIA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.43 EUR | +4.46% |
|
-0.24% | -26.95% |
| 24/04 | Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 22/03 | Adocia: announces fund-raising | CF |
| Sales 2023 | 6.05M 6.47M 539M | Sales 2024 * | 50M 53.46M 4.46B | Capitalization | 120M 129M 10.74B |
|---|---|---|---|---|---|
| Net income 2023 | -21M -22.45M -1.87B | Net income 2024 * | 26M 27.8M 2.32B | EV / Sales 2023 | 26.8 x |
| Net Debt 2023 * | 3.3M 3.53M 294M | Net cash position 2024 * | 22.5M 24.06M 2.01B | EV / Sales 2024 * | 1.96 x |
| P/E ratio 2023 * |
4.11
x | P/E ratio 2024 * |
2.27
x | Employees | 97 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.08% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +4.46% | ||
| 1 week | -0.24% | ||
| Current month | -3.77% | ||
| 3 months | -20.92% | ||
| 6 months | +15.48% | ||
| Current year | -26.95% |
1 week
7.89
8.89
1 month
7.8910.70
Current year
7.8912.40
1 year
2.7716.16
3 years
2.7516.16
5 years
2.7522.60
10 years
2.7594.24
| Managers | Title | Age | Since |
|---|---|---|---|
Olivier Soula
FOU | Founder | 53 | 16/05/16 |
Gérard Soula
FOU | Founder | 78 | 16/05/16 |
| Director of Finance/CFO | - | 01/06/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gérard Soula
FOU | Founder | 78 | 16/05/16 |
| Director/Board Member | 67 | 21/21/21 | |
| Director/Board Member | 58 | 18/13/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 8.43 | +4.46% | 84,905 |
| 25/24/25 | 8.07 | -7.77% | 106,677 |
| 24/24/24 | 8.75 | +1.51% | 28,360 |
| 23/24/23 | 8.62 | -0.69% | 36,840 |
| 22/24/22 | 8.68 | +2.72% | 61,404 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotes
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes.
At the end of 2022, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
Calendar
29/04/2024
- LSX World Congress
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.43
EUR
Average target price
9.7
EUR
Spread / Average Target
+15.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.95% | 129M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ADOC Stock
